EU/3/09/635:

Treprostinil diethanolamine

Table of contents

Overview

On 15 May 2009, orphan designation (EU/3/09/635) was granted by the European Commission to United Therapeutics Europe Ltd, United Kingdom, for treprostinil diethanolamine for the treatment of systemic sclerosis.

The sponsorship was transferred to Unither Therapeutik GmbH, Germany, in February 2019.

The sponsor's address was updated in July 2021.

Key facts

Active substance
Treprostinil diethanolamine
Intented use
Treatment of systemic sclerosis
Date of designation
15/05/2009
Orphan designation status
Positive
EU designation number
EU/3/09/635

Sponsor's contact details

Unither Therapeutik GmbH
Dieselstrasse 42
Offenbach Am Main 63071
Hassia
Germany
Tel: +49 69 98535179

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

How useful was this page?

Add your rating